memantine has been researched along with DDPAC in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD)." | 9.15 | Memantine in behavioral variant frontotemporal dementia: negative results. ( Auriacombe, S; Boutoleau-Bretonnière, C; Cerato, E; Couratier, P; Gabelle, A; Golfier, V; Lacomblez, L; Michel, BF; Puel, M; Sarazin, M; Thomas-Antérion, C; Vercelletto, M; Verpillat, P; Volteau, C, 2011) |
| "To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)." | 7.79 | A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013) |
| "We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD)." | 5.15 | Memantine in behavioral variant frontotemporal dementia: negative results. ( Auriacombe, S; Boutoleau-Bretonnière, C; Cerato, E; Couratier, P; Gabelle, A; Golfier, V; Lacomblez, L; Michel, BF; Puel, M; Sarazin, M; Thomas-Antérion, C; Vercelletto, M; Verpillat, P; Volteau, C, 2011) |
| "In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients." | 4.12 | Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022) |
| "To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)." | 3.79 | A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013) |
| "Sequential therapeutic trials for catatonoid frontal signs in clinically-evident frontotemporal dementia (n = 2) revealed differential benefits for lorazepam, amantadine, memantine, pramipexole, aripiprazole, quetiapine, citalopram, and donepezil, although certain signs also worsened." | 3.76 | Differential pharmacological responses of catatonia-like signs in frontotemporal dementia. ( Greenway, LL; Kuppuswamy, PS; Lauterbach, EC, 2010) |
| "The behavioral variant of frontotemporal dementia (bvFTD), characterized by early behavioral disorders, is a rare disease (about 5." | 2.50 | [Frontal variant of frontotemporal dementia]. ( Boutoleau-Bretonniere, C; Lebouvier, T; Vercelletto, M, 2014) |
| "There is no dedicated therapy for frontotemporal dementia (FTD)." | 2.47 | Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. ( Boxer, A; Kerchner, GA; Tartaglia, MC, 2011) |
| "A cohort of 214 Alzheimer's disease (AD) patients was used as a neurodegenerative disease reference group." | 1.91 | Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease. ( Haapasalo, A; Hartikainen, P; Katisko, K; Krüger, J; Remes, AM; Solje, E; Soppela, H, 2023) |
| "The diagnostic criteria of catatonia and frontotemporal dementia partly overlap." | 1.39 | Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy. ( Arai, H; Iseki, E; Utumi, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, A | 1 |
| Liu, C | 1 |
| Ye, W | 2 |
| Huang, D | 1 |
| She, W | 1 |
| Liu, X | 1 |
| Fung, CP | 1 |
| Xu, N | 1 |
| Suen, MC | 1 |
| Sung, HHY | 1 |
| Williams, ID | 1 |
| Zhu, G | 1 |
| Qian, PY | 1 |
| Magrath Guimet, N | 1 |
| Zapata-Restrepo, LM | 1 |
| Miller, BL | 2 |
| Perry, A | 1 |
| Hughes, LE | 1 |
| Adams, N | 1 |
| Naessens, M | 1 |
| Murley, AG | 1 |
| Rouse, MA | 1 |
| Street, D | 1 |
| Jones, PS | 1 |
| Cope, TE | 1 |
| Kocagoncu, E | 1 |
| Rowe, JB | 1 |
| Joshi, A | 1 |
| Todd, S | 1 |
| Finn, DP | 1 |
| McClean, PL | 1 |
| Wong-Lin, K | 1 |
| Katisko, K | 1 |
| Krüger, J | 1 |
| Soppela, H | 1 |
| Hartikainen, P | 1 |
| Haapasalo, A | 1 |
| Remes, AM | 1 |
| Solje, E | 1 |
| You, FL | 1 |
| Xia, GF | 1 |
| Cai, J | 1 |
| Utumi, Y | 1 |
| Iseki, E | 1 |
| Arai, H | 1 |
| Nardell, M | 1 |
| Tampi, RR | 1 |
| Boutoleau-Bretonniere, C | 2 |
| Lebouvier, T | 1 |
| Vercelletto, M | 2 |
| Blasco, H | 1 |
| Patin, F | 1 |
| Andres, CR | 1 |
| Corcia, P | 1 |
| Gordon, PH | 1 |
| Ross, L | 1 |
| Neuhaus, J | 1 |
| Knopman, D | 1 |
| Kramer, J | 1 |
| Boeve, B | 1 |
| Caselli, RJ | 1 |
| Graff-Radford, N | 1 |
| Mendez, MF | 1 |
| Boxer, AL | 1 |
| Lauterbach, EC | 1 |
| Kuppuswamy, PS | 1 |
| Greenway, LL | 1 |
| Volteau, C | 1 |
| Puel, M | 1 |
| Auriacombe, S | 1 |
| Sarazin, M | 1 |
| Michel, BF | 1 |
| Couratier, P | 1 |
| Thomas-Antérion, C | 1 |
| Verpillat, P | 1 |
| Gabelle, A | 1 |
| Golfier, V | 1 |
| Cerato, E | 1 |
| Lacomblez, L | 1 |
| Kerchner, GA | 1 |
| Tartaglia, MC | 1 |
| Boxer, A | 1 |
| Links, KA | 1 |
| Black, SE | 1 |
| Graff-Guerrero, A | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| Pollock, BG | 1 |
| Chow, TW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study[NCT02420756] | 18,488 participants (Actual) | Observational [Patient Registry] | 2016-02-29 | Completed | |||
| Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients[NCT00200538] | Phase 2 | 52 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for memantine and DDPAC
| Article | Year |
|---|---|
Advances in Treatment of Frontotemporal Dementia.
Topics: C9orf72 Protein; Cholinesterase Inhibitors; DNA-Binding Proteins; Frontotemporal Dementia; Humans; M | 2022 |
Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials.
Topics: Cognition; Dopamine Agents; Frontotemporal Dementia; Humans; Memantine; Randomized Controlled Trials | 2014 |
[Frontal variant of frontotemporal dementia].
Topics: Aged; Cholinesterase Inhibitors; Dementia; Disease Progression; France; Frontotemporal Dementia; Hum | 2014 |
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Clinical Trials as Topic; Frontotemporal Dementia; Humans | 2016 |
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agents; Frontotemporal Dementia; Humans; Mema | 2011 |
1 trial available for memantine and DDPAC
| Article | Year |
|---|---|
Memantine in behavioral variant frontotemporal dementia: negative results.
Topics: Aged; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Male; Memantine; Middle Aged; Ne | 2011 |
9 other studies available for memantine and DDPAC
| Article | Year |
|---|---|
Selective
Topics: Amyotrophic Lateral Sclerosis; Animals; Biological Products; C9orf72 Protein; DNA; Drosophila; Front | 2022 |
The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration.
Topics: Cross-Over Studies; Double-Blind Method; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; | 2022 |
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin | 2022 |
Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.
Topics: Alzheimer Disease; Delayed Diagnosis; Female; Frontotemporal Dementia; Humans; Memantine; Neurodegen | 2023 |
Behavioural Variant Frontotemporal Dementia due to
Topics: Aged; Amyotrophic Lateral Sclerosis; Cyclins; Frontotemporal Dementia; Humans; Male; Memantine; Muta | 2023 |
Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy.
Topics: Aged; Atrophy; Catatonia; Combined Modality Therapy; Dopamine Agents; Electroconvulsive Therapy; Fem | 2013 |
Off-label medication use in frontotemporal dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; California; Cholinesterase Inhibitors; Dopamine Agents; | 2010 |
Differential pharmacological responses of catatonia-like signs in frontotemporal dementia.
Topics: Aged; Amantadine; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Catatonia; Citalopram; Clinica | 2010 |
A case of apathy due to frontotemporal dementia responsive to memantine.
Topics: Aged; Apathy; Atrophy; Dopamine Agents; Follow-Up Studies; Frontal Lobe; Frontotemporal Dementia; Hu | 2013 |